Expect Intensified M&A Activity with Bio-Pharmaceutical Companies Leading to an Active 2021 & Beyond
While life sciences-focused mergers and acquisition activity in 2020 was expected to dip, at least a bit due to the […]
While life sciences-focused mergers and acquisition activity in 2020 was expected to dip, at least a bit due to the […]
Artificial intelligence (AI) will become an ever more important underlying force in the drug development process, from discovery through clinical […]
As the clinical research space continues to adapt, advance and evolve, TrialSite chronicles a number of trends, including the ongoing […]
A Rockville Maryland-based global, full-service clinical research organization (CRO) recently acquired a European-based CRO called Neox s.r.o., with over 150 […]
Private equity-backed site organization roll-up Velocity Clinical Research purchased eStudySite, contributing two trial site locations in San Diego, California to […]
Germany-based Bayer acquired AskBio’s industry leading AAV-based gene therapy platform to accelerate its ability to bring urgently needed treatments to […]
Paul Evans and Velocity are on the move again buying another research site in their quest to build a seamlessly […]
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has moved into the race to develop COVID-19 treatments, […]
Gilead Sciences (GILD) will buy cancer-focused player Forty Seven (FTSV) for $4.9 billion, the biotech company said Monday, sending FTSV stock rocketing. The deal […]
Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. to strengthen its immuno-oncology pipeline. With the acquisition Astellas gains Xyphos’ novel and proprietary […]